系统综述:参照药与英夫利西单抗生物类似药之间转换的疗效与安全性
本系统综述检索MEDLINE和EMBASE,纳入70篇相关出版物(113篇期刊论文和149篇摘要中筛选),多数为无对照观察性研究,另识别6项随机对照试验。总体证据未发现与转换相关的临床重要疗效或安全性信号,但现有研究仅报告单次转换,且多为缺乏对照组的观察性研究,需更多数据探索不同人群和场景下的转换风险。
要点
- 现有证据未发现参照药与生物类似药英夫利西单抗单次转换相关的临床重要疗效或安全性信号。
- 纳入研究多为无对照观察性研究,仅识别6项随机对照试验。
- 现有数据仅涉及单次转换,需更多数据探索不同人群和场景下的转换风险。
核心结论
- 现有数据未发现参照药与生物类似药英夫利西单抗单次转换相关的显著风险,但研究仅报告单次转换且多为缺乏对照组的观察性研究,需更多数据探索不同人群和场景下的潜在转换风险。
研究设计与样本
- 通过检索MEDLINE数据库识别已发表研究,通过检索EMBASE数据库并手动检索相关会议摘要识别会议摘要。
- 共找到113篇期刊论文和149篇摘要,其中70篇被认为相关并纳入分析。
- 大多数出版物为无对照观察性研究,识别出6项随机对照试验。
主要发现
- 总体证据未显示与转换相关的临床重要疗效或安全性信号。
关键数值与推荐
- 美国食品药品监督管理局(FDA)指南指出,为确立可互换性,研究必须证明生物类似药在多次转换后仍等效或不劣于参照产品。
局限性
- 现有研究仅报告单次转换。
- 研究大多为观察性研究,缺乏对照组。
- 需更多数据探索不同人群和场景下的潜在转换风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biosimilar versions of widely prescribed drugs, including the tumour-necrosis factor antagonist infliximab, are becoming increasingly available. As biosimilars are not identical copies of reference products, evidence may be required to demonstrate that switching between a reference biologic and biosimilars is safe and efficacious. To establish interchangeability, US Food and Drug Administration guidance states that studies must demonstrate that biosimilars remain equivalent or non-inferior to a reference product after multiple switches between products. AIMS: To investigate the evidence evaluating the safety and efficacy of switching between reference and biosimilar infliximab in patients with inflammatory disorders, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. METHODS: Published studies presenting data on switching between reference and biosimilar infliximab were identified by searching the MEDLINE database. Congress abstracts were identified by searching the EMBASE database and manually searching abstracts from relevant congresses. RESULTS: A total of 113 journal articles and 149 abstracts were found. Of these, 70 were considered relevant and included in this analysis. Most of the publications were uncontrolled, observational studies. Data from six randomised, controlled trials were identified. In general, the evidence revealed no clinically important efficacy or safety signals associated with switching. CONCLUSIONS: While available data have not identified significant risks associated with a single switch between reference and biosimilar infliximab, the studies available currently report on only single switches and were mostly observational studies lacking control arms. Additional data are needed to explore potential switching risks in various populations and scenarios.
引用
- Feagan BG, Lam G, Ma C, et al. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2018. PMID: 30411382. doi:10.1111/apt.14997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。